At ExoCure Therapeutics Company
we are transforming cancer care through groundbreaking innovation. ExoCure is developing a novel exosomal cancer treatment that addresses the flaws of conventional therapies. The company believes that with their natural compatibility, precision, and ability to overcome barriers that hinder traditional drugs, exosomes represent a transformative approach in oncology, bringing us closer to a future where exosome-based therapies become a cornerstone of a platform for cancer therapy
Introducing our Breakthrough Product
Our lead product is an exosome-based therapy aimed at treating breast and pancreatic cancers by selectively targeting overactive tumor pathways while preserving healthy cells. Initially, we use exosomes sourced from naturally cancer-resistant tissue, with plans to advance toward scalable production of human-derived exosomes from cell lines in bioreactors. In subsequent stages, these exosomes may be engineered to carry chemotherapeutic agents, enabling precise drug delivery and minimizing systemic toxicity. Administered intravenously, the therapy is designed for use as a standalone treatment or in combination with existing cancer therapies, with strong potential for adaptation across additional cancer types.
Key Features
Of Our Product
Selective
Anticancer Effect
Kills up to 90% of breast and pancreatic cancer cells in vitro, with minimal harm to healthy cells.
Innovative
& Safe
First therapy using this tissue-derived exosome approach - precise, non-toxic, and groundbreaking.
Natural & Scalable Platform
Derived from unique tissue sources, with plans for scalable bioreactor-based production using human cells
High
Market Potential
Targets fast-growing oncology markets
valued at over
$30B
Targeted Drug Delivery
Engineered to deliver therapeutic cargo (drugs, RNA, proteins) directly to tumors, reducing side effects
Versatile
IV Therapy
Administered intravenously, suitable as a standalone or combination treatment for advanced cancers
Clinically
Ready
Designed for GMP-compliant, large-scale manufacturing to support clinical and commercial use
Future Ready Platform
Expandable for other
cancers and
personalized medicine applications.
Company leadership management
Reem Miari Ph.D.
Co-Founder, CEO
Global director of Gene therapy at Orgenesis Inc., 25 years of industrial experience in leading research and developments technologies from proof of concept to clinical trials, extensive expertise in cancer biology and gene therapy, adds a valuable perspective leadership. Their combined expertise positions our startup for success in advancing and commercializing this innovative cancer treatment
Mizied Falah Ph.D.
Co-Founder, CSO
Dr. Falah is the Director and Researcher at the Medical Research Institute, Holy Family Hospital, Nazareth, and the former Director of the Research Institute at the Galilee Medical Center, Nahariya. He holds extensive expertise in biochemistry, molecular biology, and R&D leadership. Dr. Falah completed his undergraduate and master's studies in biology and biochemistry at the Hebrew University, specializing in molecular biology and biochemistry. He continued his academic journey with advanced studies at McMaster University in Hamilton, Ontario, Canada, and postdoctoral research at the Technion.
Company Leadership
Advisory Board
Mohamad Abo Nada
Our Partner
